Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
[Oral hypoglycemic agents].

Arquivos brasileiros de medicina

Golfeld S.
PMID: 5591591
Arq Bras Med. 1967 Oct-Dec;54(4):303-9.

No abstract available.

Cite
Golfeld S. Hipoglicemiantes Orais. [Oral hypoglycemic agents]. Arq Bras Med. 1967;54(4):303-9
Golfeld, S. (1967). Hipoglicemiantes Orais. [Oral hypoglycemic agents]. Arquivos brasileiros de medicina, 54(4), 303-9.
Golfeld, S. "Hipoglicemiantes Orais." [Oral hypoglycemic agents]. Arquivos brasileiros de medicina vol. 54,4 (1967): 303-9.
Golfeld S. Hipoglicemiantes Orais. [Oral hypoglycemic agents]. Arq Bras Med. 1967 Oct-Dec;54(4):303-9. Portuguese. PMID: 5591591.
Copy Download .nbib Format: NLM
SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Frontiers in public health

Shi N, Shi Y, Xu J, Si Y, Yang T, Zhang M, Ng DM, Li X, Xie F.
PMID: 34164370
Front Public Health. 2021 Jun 07;9:668368. doi: 10.3389/fpubh.2021.668368. eCollection 2021.

No abstract available.

Cite
Shi N, Shi Y, Xu J, et al. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front Public Health. 2021;9:668368doi: 10.3389/fpubh.2021.668368.
Shi, N., Shi, Y., Xu, J., Si, Y., Yang, T., Zhang, M., Ng, D. M., Li, X., & Xie, F. (2021). SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Frontiers in public health, 9668368. https://doi.org/10.3389/fpubh.2021.668368
Shi, Nanjing, et al. "SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials." Frontiers in public health vol. 9 (2021): 668368. doi: https://doi.org/10.3389/fpubh.2021.668368
Shi N, Shi Y, Xu J, Si Y, Yang T, Zhang M, Ng DM, Li X, Xie F. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front Public Health. 2021 Jun 07;9:668368. doi: 10.3389/fpubh.2021.668368. eCollection 2021. PMID: 34164370; PMCID: PMC8215266.
Copy Download .nbib Format: NLM
Glucose-Lowering Drugs and Fracture Risk-a Systematic Review.

Current osteoporosis reports

Al-Mashhadi Z, Viggers R, Fuglsang-Nielsen R, de Vries F, van den Bergh JP, Harsløf T, Langdahl B, Gregersen S, Starup-Linde J.
PMID: 33165875
Curr Osteoporos Rep. 2020 Dec;18(6):737-758. doi: 10.1007/s11914-020-00638-8. Epub 2020 Nov 09.

PURPOSE OF REVIEW: Diabetes mellitus (DM) is associated with increased fracture risk. The aim of this systematic review was to examine the effects of different classes of glucose-lowering drugs on fracture risk in patients with type 2 DM. The...

Cite
Al-Mashhadi Z, Viggers R, Fuglsang-Nielsen R, et al. Glucose-Lowering Drugs and Fracture Risk-a Systematic Review. Curr Osteoporos Rep. 2020;18(6):737-758doi: 10.1007/s11914-020-00638-8.
Al-Mashhadi, Z., Viggers, R., Fuglsang-Nielsen, R., de Vries, F., van den Bergh, J. P., Harsløf, T., Langdahl, B., Gregersen, S., & Starup-Linde, J. (2020). Glucose-Lowering Drugs and Fracture Risk-a Systematic Review. Current osteoporosis reports, 18(6), 737-758. https://doi.org/10.1007/s11914-020-00638-8
Al-Mashhadi, Z, et al. "Glucose-Lowering Drugs and Fracture Risk-a Systematic Review." Current osteoporosis reports vol. 18,6 (2020): 737-758. doi: https://doi.org/10.1007/s11914-020-00638-8
Al-Mashhadi Z, Viggers R, Fuglsang-Nielsen R, de Vries F, van den Bergh JP, Harsløf T, Langdahl B, Gregersen S, Starup-Linde J. Glucose-Lowering Drugs and Fracture Risk-a Systematic Review. Curr Osteoporos Rep. 2020 Dec;18(6):737-758. doi: 10.1007/s11914-020-00638-8. Epub 2020 Nov 09. PMID: 33165875.
Copy Download .nbib Format: NLM
[News in diabetology 2015].

Revue medicale suisse

Jornayvaz FR.
PMID: 26946699
Rev Med Suisse. 2016 Jan 13;12(500):30-1.

The year 2015 was punctuated by numerous events in diabetology. First, the ADA/EASD guidelines have been updated. The pharmacological panel for type 2 diabetes treatment saw the arrival of different new molecules. Two new basal insulins were also approved....

Cite
Jornayvaz FR. Diabétologie. [News in diabetology 2015]. Rev Med Suisse. 2016;12(500):30-1
Jornayvaz, F. R. (2016). Diabétologie. [News in diabetology 2015]. Revue medicale suisse, 12(500), 30-1.
Jornayvaz, François R. "Diabétologie." [News in diabetology 2015]. Revue medicale suisse vol. 12,500 (2016): 30-1.
Jornayvaz FR. Diabétologie. [News in diabetology 2015]. Rev Med Suisse. 2016 Jan 13;12(500):30-1. French. PMID: 26946699.
Copy Download .nbib Format: NLM
Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series.

Endocrine

Chilelli NC, Bax G, Bonaldo G, Ragazzi E, Iafrate M, Zattoni F, Bellavere F, Lapolla A.
PMID: 28421418
Endocrine. 2018 Mar;59(3):690-693. doi: 10.1007/s12020-017-1301-x. Epub 2017 Apr 18.

No abstract available.

Cite
Chilelli NC, Bax G, Bonaldo G, et al. Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series. Endocrine. 2017;59(3):690-693doi: 10.1007/s12020-017-1301-x.
Chilelli, N. C., Bax, G., Bonaldo, G., Ragazzi, E., Iafrate, M., Zattoni, F., Bellavere, F., & Lapolla, A. (2018). Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series. Endocrine, 59(3), 690-693. https://doi.org/10.1007/s12020-017-1301-x
Chilelli, Nino Cristiano, et al. "Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series." Endocrine vol. 59,3 (2018): 690-693. doi: https://doi.org/10.1007/s12020-017-1301-x
Chilelli NC, Bax G, Bonaldo G, Ragazzi E, Iafrate M, Zattoni F, Bellavere F, Lapolla A. Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series. Endocrine. 2018 Mar;59(3):690-693. doi: 10.1007/s12020-017-1301-x. Epub 2017 Apr 18. PMID: 28421418.
Copy Download .nbib Format: NLM
The dogma of "tight control": beyond the limits of evidence.

Archives of internal medicine

Finucane TE.
PMID: 16908809
Arch Intern Med. 2006 Aug 14-28;166(15):1671-2; author reply 1672. doi: 10.1001/archinte.166.15.1671-b.

No abstract available.

Cite
Finucane TE. The dogma of "tight control": beyond the limits of evidence. Arch Intern Med. 2006;166(15):1671-2; author reply 1672doi: 10.1001/archinte.166.15.1671-b.
Finucane, T. E. (2006). The dogma of "tight control": beyond the limits of evidence. Archives of internal medicine, 166(15), 1671-2; author reply 1672. https://doi.org/10.1001/archinte.166.15.1671-b
Finucane, Thomas E. "The dogma of "tight control": beyond the limits of evidence." Archives of internal medicine vol. 166,15 (2006): 1671-2; author reply 1672. doi: https://doi.org/10.1001/archinte.166.15.1671-b
Finucane TE. The dogma of "tight control": beyond the limits of evidence. Arch Intern Med. 2006 Aug 14-28;166(15):1671-2; author reply 1672. doi: 10.1001/archinte.166.15.1671-b. PMID: 16908809.
Copy Download .nbib Format: NLM
Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk.

Metabolism: clinical and experimental

La Vecchia C.
PMID: 21550082
Metabolism. 2011 Oct;60(10):1357-8. doi: 10.1016/j.metabol.2011.03.011. Epub 2011 May 06.

No abstract available.

Cite
La Vecchia C. Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism. 2011;60(10):1357-8doi: 10.1016/j.metabol.2011.03.011.
La Vecchia, C. (2011). Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism: clinical and experimental, 60(10), 1357-8. https://doi.org/10.1016/j.metabol.2011.03.011
La Vecchia, Carlo. "Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk." Metabolism: clinical and experimental vol. 60,10 (2011): 1357-8. doi: https://doi.org/10.1016/j.metabol.2011.03.011
La Vecchia C. Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk. Metabolism. 2011 Oct;60(10):1357-8. doi: 10.1016/j.metabol.2011.03.011. Epub 2011 May 06. PMID: 21550082.
Copy Download .nbib Format: NLM
A note on the A1chieve study and the importance of disseminating our results.

The Journal of the Association of Physicians of India

Shah SN.
PMID: 24482978
J Assoc Physicians India. 2013 Jan;61(1):5.

No abstract available.

Cite
Shah SN. A note on the A1chieve study and the importance of disseminating our results. J Assoc Physicians India. 2013;61(1):5
Shah, S. N. (2013). A note on the A1chieve study and the importance of disseminating our results. The Journal of the Association of Physicians of India, 61(1), 5.
Shah, Siddharth N. "A note on the A1chieve study and the importance of disseminating our results." The Journal of the Association of Physicians of India vol. 61,1 (2013): 5.
Shah SN. A note on the A1chieve study and the importance of disseminating our results. J Assoc Physicians India. 2013 Jan;61(1):5. PMID: 24482978.
Copy Download .nbib Format: NLM
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.

Nature reviews. Endocrinology

Deacon CF.
PMID: 32929230
Nat Rev Endocrinol. 2020 Nov;16(11):642-653. doi: 10.1038/s41574-020-0399-8. Epub 2020 Sep 14.

Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available molecules that interact with the catalytic site of DPP4 without disturbing...

Cite
Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642-653doi: 10.1038/s41574-020-0399-8.
Deacon, C. F. (2020). Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature reviews. Endocrinology, 16(11), 642-653. https://doi.org/10.1038/s41574-020-0399-8
Deacon, Carolyn F. "Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus." Nature reviews. Endocrinology vol. 16,11 (2020): 642-653. doi: https://doi.org/10.1038/s41574-020-0399-8
Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Nov;16(11):642-653. doi: 10.1038/s41574-020-0399-8. Epub 2020 Sep 14. PMID: 32929230.
Copy Download .nbib Format: NLM
A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs.

Expert review of clinical pharmacology

Shah SR, Iqbal SM, Alweis R, Roark S.
PMID: 30488734
Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. doi: 10.1080/17512433.2019.1552830. Epub 2018 Dec 03.

INTRODUCTION: Type 2 diabetes (T2D) is an independent risk factor for heart failure (HF). With concomitant T2D and HF, recent data suggests an incremental risk of cardiovascular death and hospitalization for HF, as compared to patients with HF without...

Cite
Shah SR, Iqbal SM, Alweis R, et al. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2018;12(1):45-52doi: 10.1080/17512433.2019.1552830.
Shah, S. R., Iqbal, S. M., Alweis, R., & Roark, S. (2019). A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert review of clinical pharmacology, 12(1), 45-52. https://doi.org/10.1080/17512433.2019.1552830
Shah, Syed Raza, et al. "A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs." Expert review of clinical pharmacology vol. 12,1 (2019): 45-52. doi: https://doi.org/10.1080/17512433.2019.1552830
Shah SR, Iqbal SM, Alweis R, Roark S. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. doi: 10.1080/17512433.2019.1552830. Epub 2018 Dec 03. PMID: 30488734.
Copy Download .nbib Format: NLM
Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.

Current drug safety

Singh M, Sharma R, Kumar A.
PMID: 30727912
Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647.

BACKGROUND: Recently, Food and Drug Administration (FDA) has approved sodium/ glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However, regarding adverse drug reactions (ADRs) of SGLT2 inhibitors in large group of population, very less information is...

Cite
Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93doi: 10.2174/1574886314666190206164647.
Singh, M., Sharma, R., & Kumar, A. (2019). Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Current drug safety, 14(2), 87-93. https://doi.org/10.2174/1574886314666190206164647
Singh, Mahakpreet, et al. "Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus." Current drug safety vol. 14,2 (2019): 87-93. doi: https://doi.org/10.2174/1574886314666190206164647
Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647. PMID: 30727912.
Copy Download .nbib Format: NLM
Antidiabetic medications in patients with heart failure.

Minerva endocrinologica

Samia El Hayek MM, Beydoun MF, Azar ST.
PMID: 27195949
Minerva Endocrinol. 2017 Mar;42(1):53-63. doi: 10.23736/S0391-1977.16.02349-X. Epub 2016 May 19.

Diabetes mellitus increases the mortality secondary to heart failure independent of hypertension and coronary artery disease. Several hypoglycemic agents are used to achieve glycemic control, of which several classes however still raise controversies in terms of safety in patients...

Cite
Samia El Hayek MM, Beydoun MF, Azar ST. Antidiabetic medications in patients with heart failure. Minerva Endocrinol. 2016;42(1):53-63doi: 10.23736/S0391-1977.16.02349-X.
Samia El Hayek, M. M., Beydoun, M. F., & Azar, S. T. (2017). Antidiabetic medications in patients with heart failure. Minerva endocrinologica, 42(1), 53-63. https://doi.org/10.23736/S0391-1977.16.02349-X
Samia El Hayek, Marylene M, et al. "Antidiabetic medications in patients with heart failure." Minerva endocrinologica vol. 42,1 (2017): 53-63. doi: https://doi.org/10.23736/S0391-1977.16.02349-X
Samia El Hayek MM, Beydoun MF, Azar ST. Antidiabetic medications in patients with heart failure. Minerva Endocrinol. 2017 Mar;42(1):53-63. doi: 10.23736/S0391-1977.16.02349-X. Epub 2016 May 19. PMID: 27195949.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries